OS Therapies Reports Clinical Data of OST-HER2 for the Treatment of Unresected Osteosarcoma in Dogs
Shots:
- OS Therapies has reported data from 2 studies assessing OST-HER2 with palliative radiation to prevent or delay amputation in dogs with unresected appendicular osteosarcoma
- Unpublished data showed tumor arrest, delayed metastases, & >500-day survival in 5/15 dogs while data published Molecular Therapy, showed early immune response from the 1st dose, with short-term survivors with defective immune response improving after 2nd/3rd doses, supporting recurrent dosing; data show OST-HER2 potential for human use
- Company will submit data to the USDA for conditional approval of its patented OST-HER2 manufacturing process, expecting launch by 2025 end; pivotal trial is planned to seek full approval in 2026
Ref: Businesswire | Image: OS Therapies
Related News:- Spirited Paw Launches Calm Chewable Wafers for Dogs and Cats
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
